Key result
Several new medications approved since 2019 reduce ischemic complications in chronic CAD.
Why the study?
Several new medications have been approved to reduce ischemic complications since the last clinical update on CCAD in 2019.
This review provides an update on chronic coronary artery disease management, highlighting new medications approved since 2019 to reduce ischemic complications.
Answers are grounded in this paper and cite their sources.
Alerts clinicians to newly approved CCAD agents; extends 2019 review while leaving comparative efficacy open.
Chronic coronary artery disease (CCAD) is a leading cause of death in the United States and many other countries. The defining pathobiology is an imbalance between the metabolic demands of the myocardium and oxygen supply, which most often results from coronary artery atherosclerosis. The classic presenting symptom of CCAD is angina, but clinical presentation varies greatly among patients. Since the last In the Clinic on CCAD (previously termed "stable ischemic heart disease") in 2019, several new medications have been approved to reduce ischemic complications.
No takes yet. Share an insight, caveat, or question.
M. Kittleson (2025) conducted a review in Chronic coronary artery disease. Several new medications have been approved since 2019 to reduce ischemic complications in patients with chronic coronary artery disease.
Synapse has enriched 10 related papers. Consider them for comparative context: